~ Our portfolio

Our portfolio companies embody the Atlas culture of collaborative, science-first, patient-centric drug development

Seeded
Incubated
Co-founded
Next-generation gene therapies by enabling delivery of large genes
Targeting RNA-modifying proteins for novel precision cancer therapies
Small molecule therapies for severe cardiovascular diseases

SWX: ATLN (2000)
Novel biologic drugs platform

Sold to BMS (2007)
Advancing novel therapies for people with rare cardiopulmonary disease

NASDAQ: AVTE (2021)
Reimagining treatments for patients with respiratory illnesses and inflammatory conditions
Restoring metabolic balance to treat NASH and serious metabolic diseases

NASDAQ: AKRO (2019)
RNAi-based drugs for severe diseases

NASDAQ: ALNY (2004)
Novel anesthetics

Sold to The Medicines Company (2015)
Targeting progranulin and lysosomal biology to treat neurodegenerative diseases
Novel cancer drugs using combinatorial chemistry

NASDAQ: ARQL (1996)
Migraine prevention therapy

Sold to Eli Lilly (2013)
Covalent irreversible inhibitors

Sold to Celgene (2012)
Cell and gene therapies for rare diseases

NASDAQ: AVRO (2018)
Novel bicyclic peptides (bicycles) and bicycle drug conjugates for cancer

NASDAQ: BCYC (2019)
Breakthrough therapies for neurological & psychiatric conditions

Sold to Novartis (2020)
Harnessing the power of the epigenome to develop precision genomic therapeutics
Precision therapeutics for genetically defined diseases
Our mission is to develop the first treatment targeting a root cause of preeclampsia
Novel antibodies for immuno-oncology

Sold to Novartis (2014)
Novel vaccine platform

Sold to Johnson & Johnson (2010)
Rapidly developing new cancer treatments for people of all ages

NASDAQ: DAWN (2021)
Population genetics for the discovery of novel drug targets

Sold to Amgen (2012)
Novel biologic therapeutics for autoimmune diseases

Sold to Celgene (2017)
Preventing axonal degeneration in patients with neurological diseases

Sold to Lilly (2020)
Innovative treatments for hematologic diseases

NASDAQ: IRON (2022)
Pioneering targeted therapies for serious muscle diseases

NASDAQ: DYN (2020)
Functional genomics-based drug discovery

NASDAQ: EXEL (2000)
Novel bispecific antibodies platform

Sold to invoX Pharma (2023)
Scalable, re-dosable, non-viral gene therapy for genetic diseases

NASDAQ: GBIO (2020)
Mouse platforms for the generation of fully human antibodies

Sold to Harbour BioMed (2016)
Therapies for rare and inflammatory diseases

NASDAQ: HZNP (2011)
Unlocking nature's regulatory mechanisms to fuel the discovery of new medicines
Targeting the innate immune system to treat cancer and inflammatory diseases

Sold to BMS (2017); Novartis (2019)
Gene editing therapies

NASDAQ: NTLA (2016)
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics
Novel therapeutics for severe respiratory diseases
Delivering novel small molecule protein degrader medicines

Nasdaq: KYMR (2020)
Among the first to leverage ADC success to develop treatments for autoimmune and inflammatory disorders
Novel therapies for severe neurodegenerative diseases

Sold to Bial in 2020
Treating cancer's toughest tumors through innovation in precision radiopharmaceuticals
Discovering precision covalent medicines for immune diseases
Novel biologics for cancer treatment

Sold to Amgen (2012)
Development of complex biosimilar products

NASDAQ: MNTA (2004)
Novel antibody discovery platform

XETRA: MOR.DE (1999)
Breakthrough computer-aided drug design for transformative medicines
Novel antibiotics

Sold to AstraZeneca (2010)
New class of regulated cell and gene therapies
Novel medicines for auto-immune diseases

Sold to BMS (2016)
Targeting regulators of innate and adaptive immunity to restore immune homeostasis
Restoring ABC transporter function for patients with serious genetic diseases
Reprogramming RNA to address undruggable drivers of disease
Next-generation oncolytic immuno-therapies for cancer treatment

NASDAQ: REPL (2018)
Enhancing synaptic integrity for treatment of neurological disorders

Sold to Alkermes (2019)
Developing highly effective and differentiated treatments for cystic fibrosis
Novel antibiotics for drug-resistant bacterial infections

NASDAQ: SPRO (2017)
Novel fibrosis therapeutic

Sold to Biogen Idec (2012)
Novel antibodies built to break through the tumor microenvironment

Sold to Coherus (2023)
Pioneering transformative new biotherapeutics for patients

NASDAQ: SYBX (2017)
Advancing medicines for allergy and inflammation

NASDAQ: THRD (2022)
mRNA vaccines and therapies

Sold to Sanofi (2021)
Target-first, rational molecular glue drug discovery platform
Novel antibodies for the treatment of I&I disorders
Next-generation ocular gene therapies for vision restoration and preservation

Sold to Novartis (2020)
Transformative treatments for people with obesity and other cardiometabolic diseases

Sold to Lilly (2023)
Harnessing the power of microglia to transform treatments for neuro-degenerative diseases

NASDAQ: VIGL (2022)
Novel therapeutics using proprietary computational chemistry

Sold to Allergan (2016)
Harnessing the immune system to defeat cancer with tumor-selective immunotherapies

NASDAQ: XLO (2021)